Baxalta Inc (BXLT) : S. Muoio added new position in Baxalta Inc during the most recent quarter end. The investment management firm now holds 70,000 shares of Baxalta Inc which is valued at $3 Million , the company said in a statement filed on May 13, 2016 with the SEC.Baxalta Inc makes up approximately 2.05% of S. Muoio’s portfolio.
Other Hedge Funds, Including , Usa Mutuals Advisors sold out all of its stake in BXLT during the most recent quarter. The investment firm sold 68 shares of BXLT which is valued $2,883. Prentiss Smith Co Inc added BXLT to its portfolio by purchasing 750 company shares during the most recent quarter which is valued at $30,878. Baxalta Inc makes up approx 0.02% of Prentiss Smith Co Inc’s portfolio.
Baxalta Inc opened for trading at $45.48 and hit $45.71 on the upside on Wednesday, eventually ending the session at $45.71, with a gain of 1.58% or 0.71 points. The heightened volatility saw the trading volume jump to 1,26,92,805 shares. Company has a market cap of $31,245 M.
On the company’s financial health, Baxalta Inc reported $0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.46. The company had revenue of $1548.00 million for the quarter, compared to analysts expectations of $1474.42 million. The company’s revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.40 EPS.
Investors should note that on May 10, 2016, Baxalta Inc announced a cash dividend of $0.0700. The company’s management has announced Jun 8, 2016 as the ex-dividend date and fixed the record date on Jun 10, 2016. The payable date has been fixed on Jul 1, 2016.
Baxalta Incorporated is a biopharmaceutical company. The Company develops manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute medical conditions. The Company also focuses on disease areas including oncology as well as technology platforms including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas including hemophilia immunology and oncology. The Company’s products include ADVATE RECOMBINATE HEMOFIL M Immunate Immunine PROTHROMPLEX TOTAL RIXUBIS FACTOR VII NF BEBULIN FEIBA OBIZUR GAMMAGARD LIQUID GAMMAGARD S/D Subcuvia HYQVIA FLEXBUMIN BUMINATE ARALAST NP GLASSIA NP CEPROTIN and ANTITHROMBIN III IMMUNO.